Evidence map›Paper›PMID 22080255›Full record

ReviewChemical communications (Cambridge, England)2012

Self-assembling peptide scaffolds for regenerative medicine.

John B Matson, Samuel I Stupp

Abstract readReview
In one paragraph

Review in Chemical communications (Cambridge, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 116 papers.

0numbers the graph read from it
0cells of the map it votes in
116citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

116 citing papers in PubMed.

  1. Article
  2. Nanostructure and Collagen-Stimulating Activity of Cationic Pentapeptide Lipopeptides.Journal of peptide science : an official publication of the European Peptide Society · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Dynamic Nanopeptide Assemblies for Trans-Tympanic Drug Delivery.International journal of nanomedicine · 2025
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. ACS biomaterials science & engineering · 2023
    Article
  17. Review
  18. Review
  19. Article
  20. Article

56 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

John B MatsonInstitute for BioNanotechnology in Medicine, Northwestern University, Chicago, IL 60611, USA.
Samuel I Stupp

Funding

Theranostic Magnetic Nanostructures for the Molecular Imaging of CancerU54CA151880 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LIN, SIMON M. · 2010 to 2014
$11.5M
Regenerative Scaffold Technologies for CNS and DiabetesR01EB003806 · NIBIB · NORTHWESTERN UNIVERSITY AT CHICAGO · PI STUPP, SAMUEL I · 2004 to 2015
$10.7M
Nanotechnology Strategies for Growth of Bones and TeethR01DE015920 · NIDCR · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SNEAD, MALCOLM L., STUPP, SAMUEL I · 2005 to 2015
$5.8M
NCI NIH HHS 1U54CA151880-01NCI NIH HHS U54 CA151880NIBIB NIH HHS 2R01EB003806-06A2NIBIB NIH HHS R01 EB003806NIDCR NIH HHS 2R01DE015920-06NIDCR NIH HHS R01 DE015920
6 · The paper itself

Abstract

Biomaterials made from self-assembling, short peptides and peptide derivatives have great potential to generate powerful new therapies in regenerative medicine. The high signaling capacity and therapeutic efficacy of peptidic scaffolds has been established in several animal models, and the development of more complex, hierarchical structures based on peptide materials is underway. This highlight discusses several classes of self-assembling peptide-based materials, including peptide amphiphiles, Fmoc-peptides, self-complementary ionic peptides, hairpin peptides, and others. The self-assembly designs, bioactive signalling strategies, and cell signalling capabilities of these bioactive materials are reported. The future challenges of the field are also discussed, including short-term goals such as integration with biopolymers and traditional implants, and long term goals, such as immune system programming, subcellular targeting, and the development of highly integrated scaffold systems.

Indexed as

AnimalsDrug CarriersEpitopesHumansPeptidesRegenerative MedicineDrug CarriersEpitopesPeptides

Identifiers

PMID22080255
PMCPMC3355058

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.